## Overview of Pros and Cons of iDose from Glaukos
**iDose TR** (travoprost intracameral implant) is an FDA-approved, sustained-release implant for reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT)[1][5][7]. It represents a new approach to glaucoma management by delivering medication directly inside the eye over an extended period, eliminating the need for daily eye drops.
—
**Pros of iDose TR**
– **Sustained, Long-Lasting Therapy**
Provides continuous medication release for up to three years, ensuring 24/7 IOP control and reducing the risk of disease progression due to missed doses[2][5][6].
– **Improved Patient Adherence**
Eliminates the need for daily eye drops, addressing the common problem of poor compliance with topical medications, especially in elderly or physically challenged patients[3][6][8].
– **Minimally Invasive Procedure**
The implant is placed via a quick, outpatient, micro-incisional procedure with minimal recovery time[2][8].
– **Reduced Side Effects Compared to Topical Drops**
Avoids ocular surface toxicity and irritation often seen with long-term topical therapy[2][6].
– **Proven Safety and Efficacy**
Clinical trials showed effective IOP reduction (up to 44% at 6 months in some studies) and a favorable safety profile, with no clinically significant corneal endothelial cell loss or serious corneal adverse events[1][3][6].
– **Decreased Dependence on Eye Drops**
In pivotal trials, 8 out of 10 patients were free of prescription eye drops 12 months after receiving iDose TR[4][5][6].
—
**Cons of iDose TR**
– **Potential Ocular Side Effects**
The most common adverse reactions (reported in 2–6% of patients) include:
– Increased intraocular pressure
– Iritis (inflammation of the iris)
– Dry eye
– Visual field defects
– Eye pain
– Ocular hyperemia (redness)
– Reduced visual acuity[1][4][5][6]
– **Surgical Risks**
As a procedural implant, iDose TR carries inherent risks related to intraocular procedures, such as infection, inflammation, or device malposition, although these are generally low[6][7].
– **Not Suitable for All Patients**
The implant is specifically indicated for OAG or OHT; patients with other forms of glaucoma or certain ocular conditions may not be candidates[1][5].
– **Long-Term Data Still Emerging**
While early and mid-term results are promising, long-term safety and efficacy beyond three years are still being studied[3][6].
—
## Summary Table
| Pros | Cons |
|———————————————-|———————————————-|
| Sustained, long-lasting IOP control (up to 3 years) | Potential for ocular side effects (2–6%) |
| Improved adherence (no daily drops) | Surgical/procedural risks |
| Minimally invasive outpatient procedure | Not suitable for all glaucoma types |
| Reduced ocular surface toxicity | Long-term safety data still emerging |
| Proven safety and efficacy in trials | |
| Decreased dependence on eye drops | |
—
**Conclusion**
iDose TR offers a significant advancement in glaucoma management by providing sustained, reliable IOP control and addressing the major challenge of patient non-adherence to topical medications. While it boasts a strong safety and efficacy profile, potential ocular side effects and procedural risks should be considered. The device is best suited for patients with open-angle glaucoma or ocular hypertension who struggle with daily eye drop regimens or require more consistent IOP control[1][2][3][4][5][6][7][8].
Citations:
[1] https://www.glaukos.com/glaucoma/products/idose-tr/
[2] https://sweeneyeye.com/glaucoma/idose-treatment/
[3] https://www.liverpool.ac.uk/centre-of-excellence-for-long-acting-therapeutics/global-news/stories/title,1503836,en.html
[4] https://www.eyecenternoco.com/blog/eye-center-of-northern-colorado-first-in-colorado-to-offer-new-vision-saving-glaucoma-treatment/
[5] https://www.idosetr.com/idosetr-overview/
[6] https://glaucomatoday.com/articles/2025-jan-feb-insert2/safe-and-effective-glaucoma-management-with-idose-tr-travoprost-intracameral-implant-75-mcg
[7] https://www.ophthalmologytimes.com/view/a-deeper-look-at-the-idose-from-glaukos
[8] https://glance.eyesoneyecare.com/stories/2024-03-04/glaukos-idose-tr-intracameral-launches-the-us/
[9] https://www.idosetr.com
[10] https://www.glaukos.com/prescribing-information/idosetr/
[11] https://www.businesswire.com/news/home/20250114301306/en/Glaukos-Announces-Positive-Clinical-Updates-for-its-iDose-Sustained-Release-Procedural-Pharmaceutical-Platform
[12] https://www.idosetr.com/important-safety-information/
[13] https://www.idosetrhcp.com
[14] https://www.nvisioncenters.com/glaucoma/idose-tr-for-glaucoma/
[15] https://www.glaukos.com/wp-content/uploads/2025/01/iDose-TR-Patient-ID-Guide.pdf
[16] https://www.reviewofoptometry.com/article/big-things-in-small-packages
[17] https://glaucomatoday.com/articles/2024-nov-dec-insert2/a-deep-dive-on-the-idosesupsup-tr-phase-2b-trial
[18] https://www.goodrx.com/idose-tr/what-is
[19] https://www.glaukos.com/wp-content/uploads/2025/01/iDoseCareConnect_HUB_HCP_card.pdf
[20] https://www.glaukos.com/wp-content/uploads/2025/01/iDose-TR-5×7-J-Code-Quick-Reference-Guide.pdf